Loading data...
Loading data...
Analyzing the stock…
70
Gathering technical, fundamental, and market data — a few seconds
Health Care · ·
$2.65
▲ $0.08 (+3.1%)
Market data updated: 09/19 11:56 PM
Fundamentals updated: 09/19/2026
News analyzed: 09/19/2026
Market Cap
$191.64M
Day Range
$2.52 - $2.67
52-Week Range
$1.22 - $3.60
Beta
—
Next Earnings
10.11.2026
Support
$2.09
Resistance
$3.34
ABOS is a stock from the Healthcare sector — Pharmaceuticals, biotech, medical devices, and health insurance — less sensitive to economic cycles, but exposed to regulation and FDA approvals.
+100.8% (1Y)
Strengths: 8/24 factors positiveRisk: Medium
This score and all analysis on this page are for informational and educational purposes only and do not constitute investment advice. Read the full disclaimer
Weighted: Technical 25% · Fundamental 20% · Growth 15% · Valuation 15% · News 10% · Quality 10% · Risk 5%
Overall Score
🟡 Mixed
Technical Trend
🔴 Bearish
Insiders
🔴 Bearish
Computed directly from the same signals behind the score above — not AI-generated.
Biggest positive driver
Leverage risk
Debt/equity: 0.44
Risk
Biggest negative driver
Daily volatility (ATR)
ATR: 7.4% of price
Risk
What to watch next
When today echoes the past.
NO RELIABLE ECHO FOUND
Only 2 historical analog(s) found after removing overlapping dates — too few for a statistically meaningful comparison.
Historical matches considered: 2
TIME ECHO identifies historical situations that resemble the current market state. Historical outcomes are not guarantees of future performance. Similarity does not imply causation, and results may change as new data becomes available.
🗓️ What Changed This Week
🌱 Building History
We don't have a real data point from a week ago for this stock yet. The weekly comparison will appear once enough history has accumulated.
📊 Score History
50
Today
—
30D
—
90D
—
1Y
🐂🐻 Investment Thesis
🐂 Bull Case
🐻 Bear Case
🔍 What Could Prove This Wrong
This isn't a price-direction forecast — just a synthesis of real, already-computed data, and future conditions that could change the picture.
🧬 STOCK DNA
This stock's profile across 8 real dimensions — a research tool, not a recommendation
Growth
38
Quality
55
Value
50
Momentum
43
Risk
46
Sentiment
80
Fundamental
50
Institutional
0
Stocks with a similar DNA right now
This stock hasn't been analyzed by StockIQAI's movement engine yet — coverage is still expanding. Check back soon.
Recent media coverage of Acumen Pharmaceuticals, Inc. has primarily focused on its **Q2 2026 financial and operational updates**, particularly progress on its lead drug candidate, **Sabirnetug**, a novel therapeutic targeting toxic amyloid beta oligomers for Alzheimer’s disease. The company highlighted advancements in clinical development, investor engagement, and participation in upcoming conferences like the **Cantor Global Healthcare Conference**. No major controversies or unrelated events were reported.
AI summary based on English-language news sources only — not investment advice.
Everyone's writing about Acumen Pharmaceuticals, Inc.. News trend score: 80. Reason: 5 of the last 20 articles are positive, versus 0 negative.
News trend analysis is based on article sentiment only, and is not investment advice or financial counsel. Read the full disclaimer
🌡️ Emotional Temperature
23
🎯 Conviction (vs. Emotion)
52
Psychology
25
Fundamentals
50
Technical
43
Valuation
50
A sharp drop, unusual volume, and negative news sentiment all at once — selling pressure that looks emotional.
Extreme momentum, price far above its moving average, and a large premium over fair value.
Price, volume, and sentiment accelerating together — a sign investors are chasing the price, not just following it.
The stock is moving in lockstep with its peers at the same intensity, rather than on its own data.
The price rise has far outpaced the actual improvement in fundamental data.
Price (3M)
+17%
Market Narrative
45
Fundamental Reality
52
Narrative Gap
-7
🔀 Psychology Acceleration
News attention/sentiment is running well ahead of the price move itself.
🧠 StockIQ Psychologist
The market behavior for ABOS suggests a dominant *euphoric* bias, as evidenced by strong momentum, significant deviation above long-term averages, and overbought technical indicators. The narrative gap is neutral, meaning sentiment aligns with observable price action, reinforcing optimism. FOMO is present but secondary, while overconfidence hints at detached valuation from fundamentals. The key open question is whether this momentum can sustain itself or if it will revert to mean, given the overbought conditions.
Updated: 09/09/2026, 01:03 AM
What could change this?
👥 What the crowd believes
"Advancing Sabirnetug (ABO-101) in Alzheimer’s disease"
"management will participate in the following upcoming investor conferences"
📈 14D Investor Psychology
Signal classification confidence: High (confidence in the behavioral read, not a price prediction). Describes observable market behavior, not what any individual investor thinks, and is not a buy/sell signal.
🏛️ Investor DNA — Historical Investors
A Historical Strategy Simulation: assuming each investor follows their documented principles, how would they rate this stock today? This is not a prediction of what they would actually do.
🟢 Best match
Walter Bagehot — 94/100
🔴 Weakest match
Thorstein Veblen — 13/100
🗣️ Why do they disagree?
The stark contrast in verdicts for ABOS reflects deep methodological divides between risk tolerance, market timing, and valuation philosophies. Walter Bagehot’s near-perfect score highlights the stock’s liquidity resilience, aligning with his focus on financial stability during crises, while Jesse Livermore’s positive trend signal suggests momentum-driven appeal. Meanwhile, value-oriented investors like Benjamin Graham and Howard Marks split on whether the stock’s fundamentals justify its price, with Graham leaning mixed and Marks cautioning about inflated expectations. On the opposite end, behavioral economists like Thorstein Veblen and Samuel Nelson flag speculative overreach, while efficient-market theorists dismiss it as unconvincing alpha. The divide underscores how defensive, growth, and contrarian strategies clash—some see stability or upward momentum, while others spot overvaluation or speculative bubbles.
Walter Bagehot
Lombard Street (1873)
🟢 94
Strong liquidity — would likely survive a real credit squeeze
Key question
Does this company have enough liquidity to survive real stress?
Fact → Principle → Simulation
Samuel Armstrong Nelson
The ABC of Stock Speculation (1903)
🟢 89
Cycle position looks favorable — closer to oversold than overbought
Key question
Is the price overextended, or is there still room to move?
Fact → Principle → Simulation
Charles Mackay
Extraordinary Popular Delusions and the Madness of Crowds (1841)
🟢 73
No obvious signs of crowd mania
Key question
Am I being swept along with the crowd, or thinking for myself?
Fact → Principle → Simulation
Benjamin Graham
Security Analysis (1934) / The Intelligent Investor (1949)
🟢 70
Attractive to a Defensive Graham Investor
Key question
Where is my margin of safety?
Fact → Principle → Simulation
Howard Marks (Market Cycle)
Mastering the Market Cycle (2018)
🟡 56
Somewhere in the middle of the cycle
Key question
Where are we in the cycle right now — near a hot extreme, or a cold one?
Fact → Principle → Simulation
Howard Marks
The Most Important Thing (2011) / Mastering the Market Cycle (2018)
🟡 53
Mixed — a good business, but expectations may already be high
Key question
What is the market probably misunderstanding about the risk here?
Fact → Principle → Simulation
Philip Fisher
Common Stocks and Uncommon Profits (1958)
🟡 50
Not enough fundamentals data for a real Fisher read
Key question
How exceptional is this business, really?
⚠️ Partial data for this stock — score is less reliable — Data availability: 0%
Edgar Lawrence Smith
Common Stocks as Long-Term Investments (1924)
🟡 50
Reasonable but not a clear long-term holding
Key question
Is this a stock I'd be happy to hold and forget about for a decade?
Fact → Principle → Simulation
Gerald M. Loeb
The Battle for Investment Survival (1935)
🟡 49
Moderate risk to capital
Key question
How much capital could I lose here if I'm wrong?
Fact → Principle → Simulation
Jack Schwager
Market Wizards (1989)
🟡 49
No clear edge either way
Key question
What's the risk/reward here, and where is my exit point?
Fact → Principle → Simulation
Benjamin Graham (Enterprising Investor)
The Intelligent Investor (1949) — the Enterprising Investor chapters
🟡 44
Not statistically cheap enough for the Enterprising Investor's looser safety bar
Key question
Is the stock statistically cheap enough to justify the extra risk?
⚠️ Partial data for this stock — score is less reliable — Data availability: 45%
Fact → Principle → Simulation
Jesse Livermore
Reminiscences of a Stock Operator (1923) / How to Trade in Stocks (1940)
🟡 43
Negative trend — against Livermore's core rule of trading with the trend
Key question
What is the price telling me right now?
Fact → Principle → Simulation
Burton Malkiel & John Bogle
A Random Walk Down Wall Street (1973) / The Little Book of Common Sense Investing (2007)
🟡 37
Mixed case — the evidence for picking this stock over an index is not strong
Key question
Do I actually have an edge here, or do I just think I do?
Fact → Principle → Simulation
Morgan Housel
The Psychology of Money (2020)
🔴 34
The kind of volatility that tends to shake patient holders out
Key question
Could I live with this volatility long enough for compounding to actually work?
Fact → Principle → Simulation
Peter Lynch
One Up on Wall Street (1989)
🔴 25
Doesn't clear Lynch's growth-at-a-reasonable-price bar
Key question
Is the growth worth the price?
⚠️ Partial data for this stock — score is less reliable — Data availability: 35%
Fact → Principle → Simulation
Thorstein Veblen
The Theory of Business Enterprise (1904)
🔴 13
Pattern Veblen would flag as growth pursued for its own sake
Key question
Is management building real value, or just building itself?
⚠️ Partial data for this stock — score is less reliable — Data availability: 45%
Fact → Principle → Simulation
Based on the last 281 trading days, calculated from real price data. Click an indicator for details and a chart.
🔴 Most indicators support a downtrend (3 bullish · 7 bearish · 1 neutral)
A market-structure read based purely on real price and volume data — not full classic Wyckoff schematic identification (Phase A-E), but a quantitative analysis of what can reliably be computed: trading ranges, "effort vs. result", volume within the range, and Spring/Upthrust detection.
The stock is in a clear uptrend with no defined trading range in the period examined.
Medium confidence
The Wyckoff Method, developed by Richard Wyckoff in the early 20th century, reads the balance of supply and demand through price and volume, based on the premise that large investors ("smart money") quietly accumulate shares before rallies and quietly distribute them before declines. The read here is based solely on real price and volume data — full, precise identification of classic Wyckoff patterns (such as Phases A-E) requires human chart-reading experience and judgment, so this is an approximate algorithmic read, not a substitute for professional analysis. This should not be considered investment advice.
Gross Margin
—
Operating Margin
—
Net Margin
—
EBITDA Margin
—
ROE
-172.3%
ROA
-98.8%
ROIC
—
EPS
-$2.00
Cash
$53.99M
Total Debt
$31.16M
Current Ratio
4.07
Debt/Equity
0.44
אין נתונים היסטוריים זמינים.
אין נתונים היסטוריים זמינים.
How is Fair Value calculated? →
Not enough cash-flow data to calculate a DCF model for this stock.
Book Value per Share
$1.16
Tangible Book Value per Share (Tangible NAV)
$1.16
Sentiment based on basic keywords (not AI) — 5 positive, 15 neutral, 0 negative out of the last 20 articles.
SeekingAlpha · 16.9.2026
Benzinga · 16.9.2026
SeekingAlpha · 16.9.2026
Yahoo · 10.9.2026
GlobeNewswire · 10.9.2026
SeekingAlpha · 10.9.2026
Yahoo · 2.9.2026
GlobeNewswire · 2.9.2026
GuruFocus.com · 12.8.2026
Moby · 12.8.2026
MarketBeat · 12.8.2026
GlobeNewswire · 12.8.2026
SeekingAlpha · 12.8.2026
SeekingAlpha · 12.8.2026
GlobeNewswire · 5.8.2026
Exec Edge · 20.7.2026
Exec Edge · 16.7.2026
Zacks · 15.7.2026
Exec Edge · 15.7.2026
Zacks · 15.7.2026
Acumen Pharmaceuticals, Inc. (ABOS) currently has a StockIQ AI score of 50/100, rated "Moderate". The score is a weighted average across up to 7 categories (technical, fundamental, growth, fair value, news, quality, risk), based on real data only.
ABOS currently scores 50/100 (Moderate) across the categories we measure. StockIQ doesn't give buy/sell recommendations — use this as one data point in your own research, not as investment advice.
ABOS's technical score is 43/100, which currently reads as neutral — based on real price/volume signals (moving averages, RSI, MACD, and more), not a prediction of what happens next.
Based on the real signals StockIQ computed: Debt/equity: 0.44; Current ratio: 4.07; Price is above the 50-day average.
Based on the real signals StockIQ computed: ATR: 7.4% of price; Calmar: -0.24 (3y annualized return -19.6% / max drawdown 82.3%); Return on equity (ROE): -172.3% (negative).
StockIQ has no recorded dividend payment history for ABOS.
Real transactions by officers and insiders, as reported to the SEC on Form 4 — 0 purchases and 8 sales out of the last 25 filings.
| Name | Transaction Type | Date | Shares | Change | Price |
|---|---|---|---|---|---|
| Porter Derrell | Exercise of Derivative Securities | 17.6.2026 | 13,040 | -13,040 | — |
| Porter Derrell | Open Market Sale | 17.6.2026 | 13,040 | -13,040 | $2.33 |
| Porter Derrell | Exercise of Derivative Securities | 17.6.2026 | 13,040 | +13,040 | $1.07 |
| Porter Derrell | Exercise of Derivative Securities | 17.6.2026 | 48,540 | +13,040 | $1.07 |
| Porter Derrell | Open Market Sale | 17.6.2026 | 35,500 | -13,040 | $2.33 |
| Porter Derrell | Exercise of Derivative Securities | 17.6.2026 | 0 | -13,040 | — |
| Porter Derrell | Open Market Sale | 16.6.2026 | 12,800 | -12,800 | $2.33 |
| Porter Derrell | Open Market Sale | 16.6.2026 | 35,500 | -12,800 | $2.33 |
| Porter Derrell | Exercise of Derivative Securities | 15.6.2026 | 6,460 | -6,460 | — |
| Porter Derrell | Exercise of Derivative Securities | 15.6.2026 | 6,460 | +6,460 | $1.07 |
| Porter Derrell | Open Market Sale | 15.6.2026 | 6,460 | -6,460 | $2.35 |
| Porter Derrell | Exercise of Derivative Securities | 15.6.2026 | 54,760 | +6,460 | $1.07 |
| Porter Derrell | Open Market Sale | 15.6.2026 | 48,300 | -6,460 | $2.35 |
| Porter Derrell | Exercise of Derivative Securities | 15.6.2026 | 13,040 | -6,460 | — |
| Fountain Nathan B | Open Market Sale | 9.6.2026 | 6,400 | -6,400 | $2.23 |
| Fountain Nathan B | Open Market Sale | 9.6.2026 | 48,150 | -6,400 | $2.23 |
| Stoppel Laura | Grant/Award from Employer | 3.6.2026 | 53,250 | +53,250 | — |
| Stoppel Laura | Grant/Award from Employer | 3.6.2026 | 35,500 | +35,500 | — |
| Golumbeski George | Grant/Award from Employer | 3.6.2026 | 53,250 | +53,250 | — |
| Golumbeski George | Grant/Award from Employer | 3.6.2026 | 35,500 | +35,500 | — |
| Ives Jeffrey L. | Grant/Award from Employer | 3.6.2026 | 53,250 | +53,250 | — |
| Ives Jeffrey L. | Grant/Award from Employer | 3.6.2026 | 35,500 | +35,500 | — |
| Porter Derrell | Grant/Award from Employer | 3.6.2026 | 53,250 | +53,250 | — |
| Porter Derrell | Grant/Award from Employer | 3.6.2026 | 35,500 | +35,500 | — |
| Stalfort John A III | Grant/Award from Employer | 3.6.2026 | 53,250 | +53,250 | — |
Official FINRA data — the number of shares open in short positions, plus daily short-sale activity.
3,163,185 shares short as of 2026-08-31 · vs. 3,367,011 on 2026-07-31
Official biweekly report (FINRA Rule 4560) — no real higher-frequency data exists for this metric.
60.2% of trading volume this week was short selling, vs. 49.0% the prior week
Based on daily short-sale volume (Reg SHO) — a different metric from the open short interest above: this is daily trading volume, not an open position, so it updates weekly rather than biweekly.
Full breakdown of every data type and its source: Data Sources · Methodology